公开(公告)号：US20220401422A1

公开(公告)日：2022-12-22

申请号：US17241981

申请日：2021-04-27

Applicant: Novartis AG

Inventor： Robin Alec FAIRHURST ,  Christine FRITSCH ,  Marc GERSPACHER ,  Jürgen Hans-Hermann HINRICHS ,  Jean-Baptiste Georges Armand LANGLOIS ,  Catherine LEBLANC ,  Tengfei LI ,  Edwige Liliane Jeanne LORTHIOIS ,  Christophe MURA ,  Cristina Montserrat NIETO-OBERHUBER ,  Milen TODOROV ,  Andrea VAUPEL ,  Nicolas WARIN ,  Rainer WILCKEN

IPC: A61K31/437 ,  A61P35/00 ,  C07D471/10 ,  C07D471/20 ,  A61K31/4747 ,  C07D491/20 ,  C07D491/22 ,  A61K31/4375 ,  C07D495/20 ,  C07D495/22 ,  A61K31/436 ,  A61K31/675 ,  A61K31/155 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/635 ,  A61K31/53

Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease.